No Data Available
AdAlta Limited (1AD)
is a publicly listed company on the Australian Securities Exchange (ASX).
About AdAlta Limited
AdAlta Limited is a drug discovery and development company focused on using its powerful technology platform to generate a promising new class of protein therapeutics, known as i-bodies, for treating a wide range of human diseases.
i-bodies are a human analogue of the antigen binding domain of the shark antibody; they combine the high target specificity and affinity advantages of antibodies with the beneficial features of small molecule drugs.
The Company’s lead i-body candidate, AD-114, is being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need. AdAlta intends to continue further discovery and development activities directed towards other disease targets for in-house development or partnering.
The Company is led by an experienced management team and Board and is supported by a world class scientific advisory board.
Both AdAlta’s i-body technology platform and lead i-body drug candidate, AD-114, are protected by a strong portfolio of worldwide granted patents and pending applications.
AdAlta is headquartered in Melbourne, Australia.
i-bodies are a promising, novel class of protein therapeutics that offer a new and potentially more effective approach to treating a wide range of human diseases. They are identified and developed using their proprietary technology platform.
i-bodies, have the exceptional targeting and antigen binding properties and carry out the functional role of recognising and binding to other molecules/antigens including disease targets to produce a therapeutic effect.
i-bodies are designed so that they mimic the shape of the antigen binding domain of shark antibodies and their key stability features; these characteristics are engineered into a human protein. As unique compounds, i-bodies have a shark-like long binding loop that is absent in human antibodies and other next generation antibodies. This long binding loop and the human protein i-body scaffold form the i-body.
i-body Key Properties and Benefits
- High target specificity and high affinity for their target
- Small proteins; 10% the size if a typical human antibody
- Highly stable to proteases, high temperatures and low pH
- Long loop for target cavity binding and alternative epitopes
- Human protein – reduces risk of immune response
Overcoming Challenging Targets
i-bodies can recognise and bind to a diverse range of different therapeutically-relevant targets including those that are difficult/intractable to access by current antibody therapies such as G-protein coupled receptors (GPCRs) and ion channels, as result of the long binding loop that is lacking in traditional antibodies.
G-protein coupled receptors (GPCRs) and ion channels have traditionally been targeted by small molecule drugs, which account for and are targeted by approximately 40% of all drugs currently on the market. Small molecules can have an increased risk of toxicity and off target side effects due to their lack of specificity. With their high affinity and specificity and long binding loop, the i-body can access GPCRs and ion channels without the off-target side effects common with small molecule drugs.
AdAlta is the pioneer of a novel technology platform that mimics the shape and engineers key stability features of the antigen binding domain of shark antibodies into human proteins to create unique compounds, known as i-bodies. Their technology platform can be used to identify novel therapeutics to a range of disease targets.
Drug Discovery and Manufacture Process
They have developed i-bodies into proprietary phage libraries containing over 2 billion i-body protein compounds. This large diverse library contains i-bodies that can bind to a broad range of therapeutically-relevant targets and can be rapidly screened in the lab against disease targets. Once i-body binders have been identified they can then be readily further improved through a process known as affinity-maturation to enhance target binding and thereby generate therapeutic lead drug candidates.
i-bodies are manufactured in bacterial systems, a more cost effective and easier method than the types of human cell culture required for conventional monoclonal antibodies. In addition they have preliminary data demonstrating that functional i-bodies can be manufactured using peptide synthesis, removing the need for bacterial manufacturing.
Their lead i-body candidate AD-114 is being developed for idiopathic pulmonary fibrosis (IPF).
They are utilising the power of their i-body technology platform to develop a pipeline of i-bodies (potential drugs), with an initial focus on treating fibrotic diseases.
Their lead i-body drug candidate AD-114 has anti-fibrotic effects in treating a type of fibrosis of the lung, known as idiopathic pulmonary fibrosis (IPF), and this is the indication that they are initially focusing on. AD-114 has also demonstrated anti-fibrotic effects in treating fibrosis of the eye and they are pursuing this as an additional indication.
They are also interested in broadening the application of AD-114 to other fibrosis indications, including demonstrating therapeutic applications for fibrosis diseases of the liver, skin, kidney and heart.
AD-114 has key advantages for IPF treatment. These include:
- specificity for diseased human tissue with effects only shown on IPF tissue and no effects displayed on normal lung tissue nor any evidence of off target effects;
- more effective than existing IPF approved drugs showing greater in vitro efficacy compared to the only approved therapies Nintedanib and Pirfenidone;
- demonstration in multiple animal models showing that AD-114 has both anti-fibrotic and anti-inflammatory effects; and
- novel mechanism of action for fibrosis enabling a “first in class” therapy.
2 Park Drive
+61 3 9479 5159
Fax: +61 2 8583 3040
The General Overview, Services, Products and Projects information for this profile was last edited on 23 Aug 2016.